Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class ...

Certa Therapeutics announces WHO grants INN 'asengeprast' to its lead candidate FT011, a novel GPR68 antagonist for chronic fibrosis. Asengeprast shows promising efficacy in Phase I and IIa SSc studies, with plans for Phase IIb trials. Certa aims to develop precision therapies for fibrotic diseases.